ArticleReproductive sciences (Thousand Oaks, Calif.)2026
Increased Asialoglycoprotein Receptor 1 Level in Granulosa Cell as a Potential Biomarker for Polycystic Ovary Syndrome.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The study investigated whether asialoglycoprotein receptor 1 (Asgr1) can serve as a biomarker for polycystic ovary syndrome (PCOS). It is known that Asgr1 loss-of-function variants are associated with lower cholesterol levels and reduced cardiovascular disease risk, but its role as a PCOS biomarker was unclear. In this clinical translational study involving 60 women undergoing IVF at the Assisted Reproductive Center of Northwest Women's and Children's Hospital in Xi'an, China (including controls and PCOS patients), Asgr1 levels in granulosa cells were significantly higher in PCOS women compared to controls (1.2 [0.6-1.8] vs. 2.0 [1.3-2.9], p < 0.001). The receiver operating characteristics curve showed Asgr1 had a predictive value of 0.747 (95%CI: 0.623-0.870) for PCOS. Among individuals with a BMI of 18.5-25 treated with a gonadotropin-releasing hormone (GnRH) agonist protocol, Asgr1 levels positively correlated with gonadotropin dosage. While this is the first study to link Asgr1 to PCOS, its sample size was limited, requiring larger cohorts to confirm Asgr1's predictive accuracy for PCOS. The findings provide a potential new biomarker for PCOS diagnosis.
Indexed as
Identifiers
41491768What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.